1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3 Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents
2.5. Assumption & Limitation
2.6. Analyst tools and models
3. Executive Summary
4. Global Benign Prostatic Hyperplasia Treatment Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Advancement/Recent Development
4.4. Regulatory Framework
4.5. Porters Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
5. Global Benign Prostatic Hyperplasia Treatment Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Treatment
5.2.1.1. Drug Class
5.2.1.1.1. Alpha-blockers
5.2.1.1.2. Alpha-reductase Inhibitor (5-ARIs)
5.2.1.1.3. Phosphodiesterase-5 Enzyme Inhibitor
5.2.1.1.4. Muscarinic Receptor Antagonist (MRA)
5.2.1.1.5. Combination Drug
5.2.1.2. Minimally Invasive Surgeries
5.2.1.2.1. Transurethral Resection of the Prostate (TURP)
5.2.1.2.2. Transurethral Incision of the Prostate (TUIP)
5.2.1.2.3. Robotic Surgeries
5.2.1.2.4. Transurethral Microwave Thermotherapy (TUMT)
5.2.1.2.5. Prostatic Urethral Lift
5.2.1.2.6. Others
5.2.1.3. Laser Therapy
5.2.1.4. Others
5.2.2. By Therapy
5.2.2.1. Mono Drug Therapy
5.2.2.2. Combination Drug Therapy
5.2.3. By End User
5.2.3.1. Hospitals
5.2.3.2. Ambulatory Surgical Centers
5.2.3.3. Specialty Clinics
5.2.3.4. Others
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. The Asia Pacific
5.2.4.4. Latin America
5.2.4.5. The Middle East and Africa
6. North America Benign Prostatic Hyperplasia Treatment Market
6.1. Market Size & Forecast by Value, 2018-2028
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By Therapy
6.2.3. By End User
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada
7. Europe Benign Prostatic Hyperplasia Treatment Market
7.1. Market Size & Forecast by Value, 2018-2028
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By Therapy
7.2.3. By End User
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. United Kingdom
7.2.4.3. Italy
7.2.4.4. France
7.2.4.5. Spain
7.2.4.6. The Netherlands
7.2.4.7. Rest of Europe
8. The Asia Pacific Benign Prostatic Hyperplasia Treatment Market
8.1. Market Size & Forecast by Value, 2018-2028
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By Therapy
8.2.3. By End User
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Australia
8.2.4.6. Indonesia
8.2.4.7. Malaysia
8.2.4.8. Rest of Asia Pacific
9. Latin America Benign Prostatic Hyperplasia Treatment Market
9.1. Market Size & Forecast by Value, 2018-2028
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By Therapy
9.2.3. By End User By Country
9.2.3.1. Brazil
9.2.3.2. Mexico
9.2.3.3. Argentina
9.2.3.4. Rest of Latin America
10. The Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
10.1. Market Size & Forecast by Value, 2018-2028
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By Therapy
10.2.3. By End User
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. Qatar
10.2.4.4. Kuwait
10.2.4.5. South Africa
10.2.4.6. Egypt
10.2.4.7. Nigeria
10.2.4.8. Rest of Middle East & Africa
11. Competitive Landscape
11.1. List of Key Players and Their Offerings
11.2. Market Share Analysis, 2021
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
12. Impact of COVID-19 on Global Benign Prostatic Hyperplasia Treatment Market
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
13.1. Abbott Laborites
13.2. Allergan plc
13.3. Astellas Pharma, Inc.
13.4. Asahi Kasei Corporation
13.5. Boehringer Ingelheim GmbH
13.6. GlaxoSmithKline plc
13.7. Pfizer, Inc.
13.8. Boston Scientific Corporation
13.9. Teleflex Incorporated
13.10. Endo International plc
13.11. Urologix, LLC
13.12. LISA Laser
13.13. Olympus Corporation
13.14. Teva Pharmaceutical Industries Ltd.
13.15. Merck & Co., Inc.
13.16. Sanofi
14. Key Strategic Recommendations
*Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable